MedTrace Logo

A Study To Evaluate The Effect Of CP-690,550 On Measures Of Kidney Function In Patients With Active Rheumatoid Arthritis

NCT01484561 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 148

Last updated 2014-04-02

Study results available
· View outcomes & findings →

Summary

The purpose of study is to explore the effect of CP-690,550 (Tofacitinib) on measures of kidney function in patients with active rheumatoid arthritis (RA).

Conditions

  • Arthritis, Rheumatoid

Interventions

DRUG

CP-690,550 or Placebo

CP-690,550 10 mg twice a day (BID) orally or placebo BID orally, approximately 72 days

DRUG

Placebo

Placebo BID orally, approximately 72 days

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2013-01-31
Completion
2013-02-28

Countries

  • United States
  • Czechia
  • Germany
  • Mexico
  • Poland
  • Russia
  • South Korea
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01484561 on ClinicalTrials.gov